Android app Apple app link

BeiGene's PD-1 drug approved in EU for first-line oesophageal cancer treatment

By Yahoo! Finance   |   1 year ago
BeiGene's PD-1 drug approved in EU for first-line oesophageal cancer treatment

The European Commission has approved Tevimbra (tislelizumab) in combination with chemotherapy as a first-line treatment for oesophageal squamous cell carcinoma and gastric or gastroesophageal junction adenocarcinoma.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.